ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Elite Pharmaceuticals Inc (QB)

Elite Pharmaceuticals Inc (QB) (ELTP)

0.53
-0.022
(-3.99%)
Closed February 18 4:00PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
0.53
Bid
0.5101
Ask
0.549
Volume
5,052,323
0.445 Day's Range 0.53
0.1213 52 Week Range 0.7598
Market Cap
Previous Close
0.552
Open
0.4501
Last Trade
38
@
0.52164
Last Trade Time
Financial Volume
$ 2,458,552
VWAP
0.486618
Average Volume (3m)
1,221,825
Shares Outstanding
1,068,273,108
Dividend Yield
-
PE Ratio
28.19
Earnings Per Share (EPS)
0.02
Revenue
56.63M
Net Profit
20.11M

About Elite Pharmaceuticals Inc (QB)

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products which have been licensed to Lannett Company, Prasco, LLC, Epic Pharma... Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products which have been licensed to Lannett Company, Prasco, LLC, Epic Pharma, LLC, and TAGI Pharma. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Carson City, Nevada, USA
Founded
-
Elite Pharmaceuticals Inc (QB) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker ELTP. The last closing price for Elite Pharmaceuticals (QB) was $0.55. Over the last year, Elite Pharmaceuticals (QB) shares have traded in a share price range of $ 0.1213 to $ 0.7598.

Elite Pharmaceuticals (QB) currently has 1,068,273,108 shares outstanding. The market capitalization of Elite Pharmaceuticals (QB) is $589.69 million. Elite Pharmaceuticals (QB) has a price to earnings ratio (PE ratio) of 28.19.

ELTP Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.00651.241642788920.52350.560.44511160620.53604704CS
40.048.163265306120.490.560.4458596120.50587328CS
12-0.0999-15.85966026350.62990.6450.44512218250.535363CS
260.3325168.354430380.19750.75980.18224219510.47427551CS
520.338176.0416666670.1920.75980.121315984310.40011904CS
1560.489051194.261294260.040950.75980.02689976280.25537615CS
2600.4395485.6353591160.09050.75980.0239720400.17953524CS

ELTP - Frequently Asked Questions (FAQ)

What is the current Elite Pharmaceuticals (QB) share price?
The current share price of Elite Pharmaceuticals (QB) is $ 0.53
How many Elite Pharmaceuticals (QB) shares are in issue?
Elite Pharmaceuticals (QB) has 1,068,273,108 shares in issue
What is the market cap of Elite Pharmaceuticals (QB)?
The market capitalisation of Elite Pharmaceuticals (QB) is USD 589.69M
What is the 1 year trading range for Elite Pharmaceuticals (QB) share price?
Elite Pharmaceuticals (QB) has traded in the range of $ 0.1213 to $ 0.7598 during the past year
What is the PE ratio of Elite Pharmaceuticals (QB)?
The price to earnings ratio of Elite Pharmaceuticals (QB) is 28.19
What is the cash to sales ratio of Elite Pharmaceuticals (QB)?
The cash to sales ratio of Elite Pharmaceuticals (QB) is 10
What is the reporting currency for Elite Pharmaceuticals (QB)?
Elite Pharmaceuticals (QB) reports financial results in USD
What is the latest annual turnover for Elite Pharmaceuticals (QB)?
The latest annual turnover of Elite Pharmaceuticals (QB) is USD 56.63M
What is the latest annual profit for Elite Pharmaceuticals (QB)?
The latest annual profit of Elite Pharmaceuticals (QB) is USD 20.11M
What is the registered address of Elite Pharmaceuticals (QB)?
The registered address for Elite Pharmaceuticals (QB) is 321 W. WINNIE LANE, #104, CARSON CITY, NEVADA, 89703
What is the Elite Pharmaceuticals (QB) website address?
The website address for Elite Pharmaceuticals (QB) is www.elitepharma.com
Which industry sector does Elite Pharmaceuticals (QB) operate in?
Elite Pharmaceuticals (QB) operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SMKGSmart Card Marketing Systems Inc (PK)
$ 0.0019
(189,900.00%)
9.86k
TVOGTurner Valley Oil and Gas Inc (CE)
$ 0.0005
(49,900.00%)
247.03k
AASZDAtlantic Sapphire AS (QB)
$ 1.09
(15,471.43%)
731
TIOGTingo Group Inc (CE)
$ 0.015
(14,900.00%)
10.34k
FPWMCharlestowne Premium Beverages Inc (CE)
$ 0.0001
(9,900.00%)
450
ZHCLFZenith Capital Corporation (CE)
$ 0.0001
(-99.90%)
150
ELYSElys BMG Group Inc (CE)
$ 0.000001
(-99.75%)
327
GRMCGoldrich Mining Company (CE)
$ 0.000001
(-99.67%)
500
THMOThermoGenesis Holdings Inc (CE)
$ 0.000001
(-99.67%)
1.16k
ELIQQElectriq Power Holdings Inc (CE)
$ 0.0015
(-99.25%)
100
AFFUAffluence Corp (PK)
$ 0.00025
(-37.50%)
230.6M
DPUIDiscount Print USA Inc (PK)
$ 0.0002
(0.00%)
188.75M
PHILPHI Group Inc (PK)
$ 0.0002
(0.00%)
161.7M
CBDDCBD of Denver Inc (PK)
$ 0.0002
(0.00%)
150.4M
HMBLHUMBL Inc (PK)
$ 0.0005
(0.00%)
143.28M

ELTP Discussion

View Posts
sharkey1 sharkey1 12 minutes ago
Yes Dr. sleep, that last CC was a very good sales pitch, Nasrat put it all out there.
I found it interesting that he mentioned they don't do Injectable's or liquids,
just out of the blue.
If a pharma already does injectables,
Well,
👍️ 1
tombe tombe 19 minutes ago
Just because you say it, does not make it true. We have surely learned that over time!!!

“If we go through this process and we either don't get the right offer or we reject the offer, then the next step is Nasdaq”
👍️ 1 💯 1
DrSleep DrSleep 21 minutes ago
Yep! I’m moving things around too from 401k. Goosebumps.
👍️0
HGilS HGilS 25 minutes ago
It takes time to move funds.
So the coming days will be interesting
👍️0
DrSleep DrSleep 38 minutes ago
Who else is thinking today could get interesting? 🙋‍♂️
👍️ 2
The ELTP King The ELTP King 1 hour ago
Both are happening.

Nasdaq then buyout.

His intention is to suggest with certainty that we are headed for a reverse split and not a buyout.
👎️ 1 🚽 1
sharkey1 sharkey1 2 hours ago
Correction, on the house bill 1396, copied from redit,

https://www.reddit.com/r/WallStreetbetsELITE/comments/1irl3m7/how_hr1396_could_impact_the_stock_market_generic/

can't find on google, it's in the ways and means committee
I think
👍️0
gebla gebla 2 hours ago
Agreed on the quality, I used a free o line AI service. But it is accurate enough to understand what was discussed.
Do you have a better tool? 
👍️0
jour_trader jour_trader 5 hours ago
Great comments from cc. Transcription was of terrible quality. So many errors. 


"Merchant acquisition" in first line. This isn't a retail store...
👍️ 1
Trend-Setter Trend-Setter 5 hours ago
M&A this year folks !!!

Q3 FY 2025 Feb. 14. 2025 CC:
Q&A session...
Is the time line for uplisting to NASDAQ or acquisition merger still on track to be around August 2026?
No. Alright. So let me let me, take a minute and talk about Nasdaq and and Merchant acquisition. We have been setting that as a goal for years now. And, the the first few months I joined the company, our previous chairman, who is extremely knowledgeable and well connected in the industry, took me to a, a New York, entity that wanted us to go to Nasdaq and have a reverse split and and even have, have us on the Israeli exchange.

And I said no because then I believe then as I believe till recently that, rushing to do something like this is extremely detrimental to the stockholders. Now things are different. We have turned Elite around. We went from a company that almost went bankrupt because the FDA and got turned down on the, our technology, And we turned things around and now we're a viable company that has profits and revenues and we are a leader in the industry in some of these products. Our fundamentals are strong and this is the time for us to seek out mergers and acquisition or Nasdaq.

So what would be the first step if we're gonna do that? The first step would be, you will sign up with a world renowned company. The top companies in in the country, Jefferies, JPMorgan, Wells Fargo, Bank of America, among others. And believe me, I've talked to them all . Then if you sign up with one of them, they will bring you suitors.

Then when the management first line management, my senior staff and I listen to these people and see that the the offer is viable, it goes to the, or we have offers that that, to entertain. It goes to the next level, which is the board of directors. Board of directors approve it. It'll go to you, the stockholders. The stockholders approve a a, the purchase, the sales acquisition, then it'll go to the SEC, and that will be it.

If we go through this process and we either don't get the right offer or we reject the offer, then the next step is Nasdaq. We have the fundamentals. We have everything that we need to go to Nasdaq. We cannot go to Nasdaq without a reverse split. K?

Now I am not as concerned because we do have fundamentals. Before, any hit, any little blip, and we would have gravitated back to the bulletin board. But now we are a strong company with current products that will last for a long time to come and future products that are in the pipeline. So we have a business continuity, and I do think we can withstand Nasdaq right now. So whatever happens is gonna go exactly in this this these two points that I outlined.

And the reason I said no to the last question is the time line for uplisting to Nasdaq or acquisition merger in August 26. It's not. The time is very near. We need to work on it now.Thank you, Matthew, and thank you, ladies and gentlemen. - CEO Nasrat Hakim

Note: Transcription Errors: Merchant = Merger

Cleaning Up the books!!!

Got a question on will the Hakim and Kaske promissory notes be paid at the end of the fiscal year?

Remember the fiscal year ends March 31, those are due on March 31. They're actually due in the first quarter of the next fiscal year and our plans are that we will pay those amounts, which total $4,000,000 when they come due, which will be in the Q1 of the 2026 fiscal year. --- CFO Carter Ward (Q3 FY 2025 CC)
Note for newbies: Q1 FY 2026 starts 43 Days from today.


NOTE 7. RELATED PARTY LOANS PAYABLE --- SEC Q3 FY 2025 page F15
The Company has entered into a collateralized promissory note with individual lenders with rates comparable to the EWB Term Loan but with fewer covenants (the “Hakim Promissory Note”). These covenants include filing timely tax returns and financial statements, and an agreement not to sell, lease, or transfer a substantial portion of the Company’s assets during the term of the Hakim Promissory Note. On June 2, 2023, the Company entered into a Promissory Note with Nasrat Hakim, CEO and Chairman of the Board of Directors, pursuant to which the Company borrowed funds in the aggregate principal amount of $3,000,000. The Hakim Promissory Note has an interest rate of 9% for the first year and 10% for an optional second year and the proceeds were used for working capital and other business purposes. The original maturity date of the Hakim Promissory Note was June 2, 2024, with an optional second year extension. The second year extension was exercised pursuant to the terms of the Hakim Promissory Note.

On June 30, 2023, the Company entered into a collateralized promissory note with Davis Caskey (the “Caskey Promissory Note”). The Caskey Promissory Note has a principal balance of $1,000,000 and an interest rate of 9% for the first year and 10% for an optional second year. The Caskey Promissory Note is subject to the same covenants as are contained in the Hakim Promissory Note. The proceeds will be used for working capital and other business purposes. The original maturity date of the Caskey Promissory Note was June 30, 2024, with an optional second year extension. The second year extension was exercised pursuant to the terms of the Caskey Promissory Note.

First Hint of M&A Due Diligence Started? Q1 FY 2025 Aug. 15, 2024 CC:
Everyone I speak to regarding Elite financials, they evaluate the warrants and their impacts separately, depending upon the nature of the analysis that they're conducting. So we disclose as per GAAP, the warrants are easily identified and whosever's evaluating our company can either include them or exclude them depending upon the nature of their evaluation. That's really what happens. So to sum things up, our financials continue on the growth trajectory. Revenues are up, profits are up, working capital is increasing, debt is low. - CFO Carter Ward


It's Happening NOW !!!..... GO ELITE TEAM !!! GO LONGS !!!
👍️ 1 💯 1
The ELTP King The ELTP King 6 hours ago
As if this isn't publicly available info which can be found in the latest 10-K...

He lied about the number of shares owned my Nasrat and the rest.
👍️0
tombe tombe 6 hours ago
Didn’t mention the 200 mil owned by Milkah?
👍️ 1
HGilS HGilS 6 hours ago
The lying king did it again. He lied about the number of shares owned my Nasrat and the rest.
👍️0
Jimmy Joe Jimmy Joe 6 hours ago
Baylander, pharmaceuticals whether injectables or solid dosage doesn't work like that. Things come up and not everything runs as planned.
Delays happen, get over it.
It's like when a healthy ticker does a reverse split and instead of having 100 shares at $1/share the person now has 10 shares at $10/share.
Nothing has changed. Elite still made money that will go into next Q.

I heard Draft Kings was coming out with a new Quarterly betting app for stocks. Now if you had that app and thought Elite would have been on schedule then I can see where you may have a point. Maybe Nasrat has the same app~? Maybe they fixed it so that the shipment would be late~? Like a blown ref call in a football game.

I dunno...........

$ELTP baby~!
😹 2 😻 1
The ELTP King The ELTP King 6 hours ago
It appears the general consensus on iHub is we won't accept a buyout in 2025 for anything less than $2.00

Thanks.
👍️0
tombe tombe 6 hours ago
Now you’re just trying to make it appear as though there is some sort of drama going on between the board voting to approve a buyout price that “we the shareholders” will get screwed by and that we all understand that we have the power to vote it down.

LMAO.
👍 1
jour_trader jour_trader 6 hours ago
He also has Mikah, which owns 50% of Adderall rights. That is additional leverage in pricing negotiations beyond just Elite % ownership that he has.
👍️0
The ELTP King The ELTP King 7 hours ago
Folks, don't listen to the continued lies as shown in the quote below.

Nasrat and The Board of Directors have VERY LITTLE voting power in a future buyout price:

Percent Ownership of ELTP:
22.34% - Nasrat Hakim and the ENTIRE Board of Directors
77.66% - Regular shareholders

The price will be the price and we will accept it. All of us. And he will decide because he has majority.
👶 1
HGilS HGilS 8 hours ago
Yours appear in bold and black ink. in my list. Hard not to see your posts.
👍️0
sportsbook14 sportsbook14 8 hours ago
IDK what you re referring to. As far as I can see our ID's are the same. Yours has a dollar sign after your name being the only difference.
👍️0
HGilS HGilS 8 hours ago
50 thumbs up and 54 comments on Reddit penny stocks.
🎓️ 1 👍️ 1
HGilS HGilS 8 hours ago
Blasphemy!!!

I just want this to be clear. No one will be happy with the same number we get.

Some of us own millions of shares. Some thousands. Some of us are here for more than 10 years.

The price will be the price and we will accept it. All of us. Because between mikah and Nasrat shares he will be a billionaire. And he will decide because he has majority.

Do you remember for 10 years at cents, ? You and your friends should have covered a long time ago.

Buyout now!!!
👍️ 1
IB_ IB_ 8 hours ago
I know you will defend ANYTHING your deity decides to do, but if you don't mind the next time you pray to nasrat, ask him to either sell the company for what you said,"$4-$6" per share by July OR just continue to grow the company and share price organically !!!!!!!!!

Hopefully he answers your prayers,

IB_🤴
🌈 1 💤 1
HGilS HGilS 8 hours ago
The ball may already be rolling. Some debts were paid. More will be paid by July. Do you remember how quick Carter was to give the correct timing for the two loans to be paid back? In q1 2026.
👍️ 2
NASDAQ2020 NASDAQ2020 8 hours ago
He has spoken with all of the M&A advisory firms.
He just has to pick one to get the ball rollin’

ELTP
👍️ 4
HGilS HGilS 9 hours ago
Nasrat did say he spoke to all of them. In the cc
👍️ 2
Maxthedog Maxthedog 9 hours ago
I thought Nasrat wanted to sell the company, like selling a house. If it's not for sale, no one will come around, and didn't he say he hasn't spoken to any of the large brokerage firms about this idea. But he did mention on the conference call the time might be right. So maybe, Nasrat might start talking to some large banker firms to see if there an attraction for a possible buyout or merger before a reverse split. I don't think he wants to hang around for the next 10 years.
👍️0
jour_trader jour_trader 9 hours ago
It may have been on their mind as a strategic possibility, but it shouldn't take nearly that long once you get the ball rolling. 

I typically see 6 months for an acquisition, but then again have seen disasters where it takes a couple of years.
👍️0
HGilS HGilS 9 hours ago
I would say at least since Feb 2024. Remember the comment about buyout 5 years?
👍️0
jour_trader jour_trader 9 hours ago
He clearly said Aug 2026 is out of the question. They have been working on it behind the scenes. We just don't know for how long and where they are in the process. 
👍️ 1
NASDAQ2020 NASDAQ2020 9 hours ago
Reverse splits are a sign of good things for companies on the way up, but a sign of bad things for companies on the way down.
In order to meet the minimum share price requirements for Nasdaq, many companies will conduct a reverse split. This is perfectly acceptable to the exchange, and the post-splitshare price will be evaluated accordingly.
Using a reverse split to raise the share price and obtain an uplisting is a very positive sign for a company and is much different than companies that use a reverse split to prevent being delisted. Once again, the confusion relates to delisting as opposed to uplisting. Novice investors who don't focus on uplistings only encounter reverse splits in the context of companies that are trying to stave off a delisting, so in many people's eyes a reverse split is a sign of a troubled company.

ELTP
👍️ 2
HGilS HGilS 10 hours ago
How do you do the fancy ID in bold?

I want the same. Thx
👍️0
tombe tombe 10 hours ago
Yup. They started talking 2027 a while ago again with certainty.
👍️ 2
HGilS HGilS 10 hours ago
They need to reach 2027 so they can offload their millions of shares
👍️ 2 💯 1
tombe tombe 10 hours ago
His intention is to suggest with certainty that we are headed for a reverse split and not a buyout. As many people are afraid of reverse splits, this would help to scare people from buying the stock. Just having the reverse split conversation at the top of the board is a win for him
👍️ 2
HGilS HGilS 10 hours ago
It did mention an r/s but only if the buyout does not work.

I agree plan b should be in our drawer.
👍️0
DividendGamer DividendGamer 10 hours ago
I don't think their latest conference call mentioned a reverse split. Probably best to not spread FUD. Keep it to the facts/fundamentals. Don't want to see this turn into another wallstreetbets lol.
👍️ 1 🩳 1
HGilS HGilS 11 hours ago
The day of the r/s, your shares value will be the same before and after the r/s. If the r/s happens the day of the quarterly result, after hour. If we have a good quarter it will go up. If we had a bad quarter it will go down. Look at hut when they moved to Nasdaq. They did very well.
🎓️ 1
sportsbook14 sportsbook14 11 hours ago
Thanks. My next Q is how would this make us more money. I am sitting on 1.6 million shares. This would turn into 160k. if the price is 4 bucks a share. That would be 640K....I have more than that dollar wise now.....So why do you assume it will rise? Sadly, and yeah I know our fundamentals are great, I think it will fall back to 2, 3 bucks a share and we will all be out money instead of selling for a buck fifty now.
🩳 1
tombe tombe 11 hours ago
Must I remind you again that many things you post with such certainty do not happen? Credibility Shot!!
👍️ 3 💯 2
mrwrn2010 mrwrn2010 11 hours ago
Not 100% (fact check me) but I want to say it worked out well for JAZZ also.

However, I agree with you. Not worth the risk, IMO.
👍️ 3 💯 2 😘 1
The ELTP King The ELTP King 12 hours ago
As I posted on February 15, it will be a 1 for 10 reverse split:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175813796

what is your thinking ( General you )about the #? Will it be 10-1? 4-1?
👍️ 1 🥳 1
The ELTP King The ELTP King 12 hours ago
I am EXTREMELY happy about the upcoming reverse split to get on the Nasdaq.

It's literally a WIN-WIN-WIN situation.

Here's how:

✅️ Institutions can now buy ELTP stock. This will drive up the PPS, provide stabilization, and create investor awareness.

✅️ ALL Individuals can now buy ELTP stock. All the TENS OF MILLIONS of people who's brokerages don't allow OTC stocks can now buy in. And all the Reddit users complaining on a DAILY basis that they can't buy ELTP will now be able to buy. Just like with the institutions as evidenced above, this will drive up the PPS, provide stabilization, and create investor awareness.

✅️ You can now buy ELTP on margin. THIS is my FAVORITE reason why we need to uplist. I am going to MAX OUT the margin loan at my brokerage which will cause me to make an EXTRA six to seven figures upon the buyout.

I am not happy about the possibility of a R/S. I Know I know. That said, if we do not get acquired or merged, what is your thinking ( General you )about the #? Will it be 10-1? 4-1? I don't even know how to mathematically figure out something like this.
That said, I am confident we have been shopped around and it is HAPPENING NOW. Like the poster said below.....I did make a shit ton of money when ZGNX did a r/s. But that is the only co. that it ended up not being a bad thing. I do think our fundamentals are strong though.
👍️ 1
Dr Speculator Ninja Dr Speculator Ninja 13 hours ago
Likely even more cash on hand if you take into account $ELTP booked $12.5 MILLION in January alone. 💰️🚀
👍️ 5
sportsbook14 sportsbook14 13 hours ago
I am not happy about the possibility of a R/S. I Know I know. That said, if we do not get acquired or merged, what is your thinking ( General you )about the #? Will it be 10-1? 4-1? I don't even know how to mathematically figure out something like this.
That said, I am confident we have been shopped around and it is HAPPENING NOW. Like the poster said below.....I did make a shit ton of money when ZGNX did a r/s. But that is the only co. that it ended up not being a bad thing. I do think our fundamentals are strong though.
👍 5 📣 1
Bngo Bngo 13 hours ago
ELTP will continue to rocket upward like two years ago.

Imagine what ELTP's price per share could be soon...

Elite's stock price was in the 
$0.03 - $0.05 range until 
Adderal IR ($400 million market) & Adderall ER ($800 million market) came along.
Now it is $0.53.

What will ELTP's share price be with 4 new drugs recently launched, 2 more drugs on deck to be launch, and 2 more pending launches, and 1 pending positive BE study?

1. Methotrexate launched on 8/27/24 ~ $63 Million market  

2. Codeine with acetaminophen launched on 10/7/24 
~$47 Million market 
3. Hydrocodone with acetaminophen launched on 12/2/24 
~$300 Million market 

4. Generic Vyvanse launched on 12/26/24 
~$4.3 Billion martket 
Pending launch of generic Percocet before 4/1/25~$500 million market 
Pending launch of methadone~$30 million market
Pending launch of generic Adderall in Israel with Dexcel and possibly generic Vyvanse
Pending launch of generic OxyContin~$700 Million market 
Pending positive BE study with generic ?Concerta CNS Stimulant? ~$1.2 Billion Market
Many of us will be financially free soon and be able to retire from Elite's success story..
👍 10 🚀 4
rocioyogi rocioyogi 14 hours ago
Hello, not gonna be able to sleep tonight tomorrow’s gonna be so good and again maybe not you know how this thing plays but I’m ready for it either way, but ladies and gentlemen late this summer we’re all gonna be so happy it’s crazy 😎
👍️ 9 💥 2 🙋 1
HGilS HGilS 15 hours ago
Elite Pharmaceuticals Inc (ELTP) Q3 2025 Earnings Call Highlights: Record Revenue Growth Amid Operational Challenges
Elite Pharmaceuticals Inc (ELTP) reports a 35% year-to-date revenue increase, driven by new product launches, despite facing shipment delays and rising expenses.
Author's Avatar
GuruFocus News
2 days ago

Release Date: February 14, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points
Elite Pharmaceuticals Inc (ELTP, Financial) reported a significant increase in year-to-date revenues, reaching $52 million, a 35% growth compared to the previous year.
The company successfully launched its generic lisdexamphetamine product, contributing to record-high revenues in January 2025.
Elite Pharmaceuticals Inc (ELTP) has a strong market share in amphetamine IR, commanding 17% of the market.
The company is in its best financial position ever, with strong fundamentals, low debt, and increasing working capital.
Elite Pharmaceuticals Inc (ELTP) is positioned for future growth with upcoming product launches and a focus on R&D.
Negative Points
Total revenues for the quarter decreased by 8% compared to the same quarter last year, primarily due to shipment delays.
R&D and GNA expenses increased significantly, with R&D up by 28% and GNA by 59%, impacting overall profitability.
The company faces challenges with DEA-imposed quotas on opioid sales, limiting potential revenue from these products.
Regulatory compliance costs have increased, adding to the company's operational expenses.
There are uncertainties regarding the launch timelines for some products due to regulatory and market conditions.
Q & A Highlights
Q: Can you provide more details on the impact of the delayed shipments on Elite Pharmaceuticals' financial results for the quarter?
A: Carter Ward, CFO, explained that the total revenues for the quarter were $14.4 million, an 8% decrease from the previous year due to shipment delays caused by the Christmas and New Year holidays. These delays affected both existing product lines and the full commercial launch of the generic Vyvanse, which were shipped in early January instead. This resulted in January 2025 being a record month for shipments and revenues, almost matching the entire quarter's performance.

Q: How is Elite Pharmaceuticals managing its R&D and G&A expenses, and what are the expectations for future product development?
A: Carter Ward, CFO, noted that R&D expenses increased by 28% and G&A expenses by 59% compared to the previous year. R&D is crucial for future product development, with ongoing efforts to ensure a continuous flow of new products. The increase in G&A is attributed to higher regulatory costs and temporary expenses related to a new facility, which has now been approved and will enhance packaging capacity.

Q: What is the status of Elite Pharmaceuticals' new facility, and how will it impact operations?
A: Nasrat Hakim, CEO, stated that the new 34,000 square foot facility has been approved and will more than double packaging capacity, addressing previous bottlenecks. This expansion will also free up space for additional manufacturing suites, supporting future growth and operational efficiency.

Q: Can you elaborate on Elite Pharmaceuticals' strategic plans for future growth and market positioning?
A: Nasrat Hakim, CEO, emphasized that Elite is in its best financial position ever, with plans to continue growing through new product launches, including generic Vyvanse and other upcoming products. The company is also exploring opportunities for mergers, acquisitions, or uplisting to NASDAQ, now that it has strong fundamentals in place.

Q: How is Elite Pharmaceuticals addressing the challenges related to opioid regulations and quotas?
A: Nasrat Hakim, CEO, explained that opioid regulations are complex, with quotas set by the DEA limiting the amount that can be sold. Elite is currently facing more demand than its quota allows and is working through the regulatory process to potentially increase its quota. The company is also navigating varying state regulations and fees to ensure compliance and profitability.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.
👍️ 7 💥 1
sharkey1 sharkey1 16 hours ago
OK, THX
👍️0
HGilS HGilS 16 hours ago
What about BSX?
Boston Scientific Corporation (BSX) is a well-known medical device company. Here are some key points about its stock performance and historical data:

Stock Performance
Recent Price: As of February 7, 2025, the stock price closed at $105.25.

52-Week Range: The 52-week high is $107.17, and the 52-week low is $64.55.

Average Price: The average stock price for the last 52 weeks is $80.22.

Historical Data
2025: The stock price has shown a significant increase, with a year-to-date change of 17.83%.

2024: The stock price increased by 54.51%, reflecting strong performance.

2023: The stock price increased by 24.94%, indicating steady growth.

Impact of M&A Announcements
While I couldn't find specific instances of Boston Scientific's CEO announcing the hiring of an M&A firm, such announcements typically lead to initial stock price surges due to investor optimism. The long-term impact depends on the success of the M&A activities and overall market conditions.
👍️ 2

Your Recent History

Delayed Upgrade Clock